CN116693440A - Method for removing palladium catalyst in Irelance intermediate VI synthesis process - Google Patents
Method for removing palladium catalyst in Irelance intermediate VI synthesis process Download PDFInfo
- Publication number
- CN116693440A CN116693440A CN202310563045.9A CN202310563045A CN116693440A CN 116693440 A CN116693440 A CN 116693440A CN 202310563045 A CN202310563045 A CN 202310563045A CN 116693440 A CN116693440 A CN 116693440A
- Authority
- CN
- China
- Prior art keywords
- ivankaser
- palladium
- add
- organic phase
- palladium catalyst
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D17/00—Separation of liquids, not provided for elsewhere, e.g. by thermal diffusion
- B01D17/02—Separation of non-miscible liquids
- B01D17/0208—Separation of non-miscible liquids by sedimentation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/584—Recycling of catalysts
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
技术领域technical field
本发明涉及伊万卡塞中间体的合成方法,具体涉及一种伊万卡塞中间体VI合成工艺中钯催化剂的清除方法,属于药物合成技术领域。The invention relates to a synthesis method of an Ivankaser intermediate, in particular to a method for removing a palladium catalyst in the synthesis process of the Ivanassert intermediate VI, and belongs to the technical field of drug synthesis.
背景技术Background technique
继发性甲状旁腺功能亢进症(SHPT)是慢性肾脏病(CKD)患者常见且严重的并发症,是直接导致CKD患者心血管并发症的重要病理基础。在SHPT患者体内,由于甲状旁腺响应肾功能下降和矿物质代谢受损,甲状旁腺激素(PTH)会过度分泌,这会导致骨组织大量流失钙和磷酸盐。目前治疗SHPT的疗法包括营养治疗、营养性维生素D、活性维生素D及其类似物、拟钙剂、磷结合剂等。Secondary hyperparathyroidism (SHPT) is a common and serious complication in patients with chronic kidney disease (CKD), and it is an important pathological basis that directly leads to cardiovascular complications in CKD patients. In SHPT patients, parathyroid hormone (PTH) is oversecreted in response to decreased renal function and impaired mineral metabolism, which leads to massive loss of calcium and phosphate from bone tissue. Current treatments for SHPT include nutritional therapy, nutritional vitamin D, active vitamin D and its analogues, calcimimetics, and phosphorus binders.
伊万卡塞是一种芳基烷基胺化合物,其基本信息如下:Ivankaser is an arylalkylamine compound, the basic information of which is as follows:
中文化学名:4-((S)-3-(((R)-1-(1-萘基)乙基)氨基)-1-吡咯烷基)苯乙酸;Chinese chemical name: 4-((S)-3-(((R)-1-(1-naphthyl)ethyl)amino)-1-pyrrolidinyl)phenylacetic acid;
英文化学名:4-((S)-3-(((R)-1-(1-naphthalenyl) ethyl) amino)-1-pyrrolidinyl) phenyl acetic acid;English chemical name: 4-((S)-3-(((R)-1-(1-naphthalenyl) ethyl) amino)-1-pyrrolidinyl) phenyl acetic acid;
化学结构:Chemical structure:
; ;
分子式:C24H26N2O2;Molecular formula: C 24 H 26 N 2 O 2 ;
分子量:374.20。Molecular weight: 374.20.
伊万卡塞作为一种钙敏感受体(CaSR)激动剂,可提高CaSR对钙离子的敏感性,直接抑制PTH的分泌和甲状旁腺细胞的增殖,从而降低血液PTH浓度。本品不会增加肠道对钙和磷的吸收,从而避免了活性维生素D等药物可能引起的血钙和血磷升高。伊万卡塞于2018年首次获批用于治疗继发性甲状旁腺功能亢进,于2019年获批用于治疗无法接受甲状旁腺切除术或甲状旁腺切除术后复发的甲状旁腺癌或原发性甲状旁腺功能亢进患者的高钙血症。As a calcium-sensing receptor (CaSR) agonist, Ivankacel can increase the sensitivity of CaSR to calcium ions, directly inhibit the secretion of PTH and the proliferation of parathyroid cells, thereby reducing the concentration of PTH in blood. This product will not increase the intestinal absorption of calcium and phosphorus, thus avoiding the increase of blood calcium and phosphorus that may be caused by active vitamin D and other drugs. Ivankaser was first approved in 2018 for the treatment of secondary hyperparathyroidism and in 2019 for the treatment of parathyroid cancer that is not amenable to parathyroidectomy or has recurred after parathyroidectomy or hypercalcemia in patients with primary hyperparathyroidism.
目前伊万卡塞的合成方法主要采用以下反应路线进行:At present, the synthetic method of Ivanka Se mainly adopts the following reaction route to carry out:
合成方法一:Synthetic method one:
该合成方法路线简单,可行性高,但存在的不足是:步骤(1)使用的三氟甲磺酸的酸性较强,反应条件苛刻,且价格较为昂贵;对步骤(2)产物的拆分过程复杂,冗余工序较多,浪费严重。This synthetic method has a simple route and high feasibility, but the disadvantages are: the trifluoromethanesulfonic acid used in step (1) has strong acidity, harsh reaction conditions, and relatively expensive; the resolution of the product of step (2) The process is complicated, there are many redundant processes, and the waste is serious.
合成方法二:Synthetic method two:
该合成方法的特点与合成方法一相似,但也采用了较多的特殊原料,导致成本过高,工序操作复杂。The characteristics of this synthesis method are similar to the synthesis method 1, but more special raw materials are also used, resulting in high cost and complicated operation.
合成方法三:Synthetic method three:
该合成方法较为妥善,使用的原料均为廉价易得的化工原料,工序操作合理,无明显冗余步骤;但步骤(4)使用了钯催化剂,导致中间体VI中残留钯易超标,影响伊万卡塞最终产品的质量,存在药品安全问题隐患。This synthesis method is relatively proper, the raw materials used are all cheap and easy-to-obtain chemical raw materials, the process operation is reasonable, and there are no obvious redundant steps; but step (4) uses a palladium catalyst, which leads to the residual palladium in the intermediate VI easily exceeding the standard, which affects the I The quality of Vancaser's final product has hidden dangers of drug safety.
发明内容Contents of the invention
本发明的目的在于解决现有伊万卡塞的合成方法存在的上述缺陷,在优选的伊万卡塞合成方法(合成方法三)的基础上,提供一种伊万卡塞中间体VI合成工艺中钯催化剂的清除方法。The purpose of the present invention is to solve the above-mentioned defects in the existing Ivankasel synthesis method, and provide a synthesis process for Ivankaset intermediate VI on the basis of the preferred Ivankaset synthesis method (synthesis method 3) The removal method of palladium catalyst in medium.
本发明所涉及的伊万卡塞中间体VI的化学结构如下:The chemical structure of the Ivankaser intermediate VI involved in the present invention is as follows:
; ;
其对应的合成步骤如下:Its corresponding synthetic steps are as follows:
。 .
本发明的技术解决方案:一种伊万卡塞中间体VI合成工艺中钯催化剂的清除方法,针对合成工艺中使用的醋酸钯催化剂,综合使用L-半胱氨酸、活性炭和除钯硅胶作为吸附剂完成钯残留的控制,具体步骤如下:Technical solution of the present invention: a method for removing the palladium catalyst in the Ivankaser intermediate VI synthesis process, aiming at the palladium acetate catalyst used in the synthesis process, L-cysteine, activated carbon and palladium-removing silica gel are used comprehensively as The adsorbent completes the control of palladium residues, and the specific steps are as follows:
(1)通过钯催化剂,由伊万卡塞中间体V合成伊万卡塞中间体VI,反应结束后加水静置分液;具体操作包括:(1) Ivankaser intermediate VI is synthesized from Ivankaser intermediate V through palladium catalyst, and after the reaction is completed, add water and let it stand for liquid separation; specific operations include:
①于反应器中加入伊万卡塞中间体V 2.5倍(V:m)量的质量分数为10%的氢氧化钠和伊万卡塞中间体V 8倍(V:m)量的二甲苯,升温至40~60℃,加入伊万卡塞中间体V,搅拌分液,取上层有机相;① Add 10% sodium hydroxide with a mass fraction of 2.5 times (V:m) of Ivankaser intermediate V and 8 times (V:m) of xylene in the amount of Ivankaser intermediate V in the reactor , heat up to 40~60°C, add Ivankaser intermediate V, stir and separate, and take the upper organic phase;
②将有机相用伊万卡塞中间体V 2.5倍(V:m)量的纯化水洗涤一次,依次加入伊万卡塞中间体V 1.25倍(eq)量的4-溴苯乙酸甲酯、伊万卡塞中间体V 3.5倍(eq)量的碳酸铯、伊万卡塞中间体V 0.01倍(m:m)量的醋酸钯和伊万卡塞中间体V 0.04倍(m:m)量的2-二环己基膦-2',4',6'-三异丙基联苯,氮气置换三次,升温至100℃~120℃,反应4~5小时;②Wash the organic phase once with purified water that is 2.5 times (V:m) of Ivankaser intermediate V, and then add 4-bromophenylacetic acid methyl ester, 1.25 times (eq) of Ivankaser intermediate V Ivankaser intermediate V 3.5 times (eq) cesium carbonate, Ivankaser intermediate V 0.01 times (m:m) palladium acetate and Ivankaser intermediate V 0.04 times (m:m) Amount of 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, replaced by nitrogen three times, heated to 100°C~120°C, and reacted for 4~5 hours;
③反应结束,加入伊万卡塞中间体V 10倍(V:m)量的纯化水,充分搅拌后静置分液。③After the reaction is finished, add purified water with an amount 10 times (V:m) of Ivankaser intermediate V, stir well and let stand to separate the liquid.
(2)取步骤(1)分液后的有机相,依次用半胱氨酸水溶液和氯化钠溶液洗涤;具体操作包括:(2) Take the organic phase after liquid separation in step (1), and wash it with cysteine aqueous solution and sodium chloride solution in turn; specific operations include:
①取分液后的有机相,加入伊万卡塞中间体V 6倍(V:m)量的质量分数为2%的L-半胱氨酸水溶液,充分搅拌并分液,重复上述操作;①Take the organic phase after liquid separation, add 2% L-cysteine aqueous solution with a mass fraction of 6 times (V:m) of Ivankaser intermediate V, fully stir and separate liquid, repeat the above operation;
②再取分液后的有机相,加入伊万卡塞中间体V 6倍(V:m)量的质量分数为25%的氯化钠溶液,充分搅拌并分液,完成洗涤步骤。②Take the organic phase after liquid separation, add 25% sodium chloride solution with a mass fraction of 6 times (V:m) of Ivankaser intermediate V, fully stir and separate liquids, and complete the washing step.
(3)取步骤(2)洗涤后的有机相,加入活性炭搅拌吸附,滤除活性炭;具体操作包括:(3) Take the organic phase after washing in step (2), add activated carbon to stir and absorb, and filter out the activated carbon; specific operations include:
取有机相,加入伊万卡塞中间体V 0.1倍(m:m)量的活性炭,搅拌0.5~2小时,垫适量硅藻土过滤活性炭,用适量二甲苯淋洗滤饼,得到滤除活性炭的滤液。Take the organic phase, add 0.1 times (m:m) activated carbon of Ivankaser intermediate V, stir for 0.5~2 hours, filter the activated carbon with an appropriate amount of diatomaceous earth, rinse the filter cake with an appropriate amount of xylene, and obtain the filtered activated carbon of the filtrate.
(4)取步骤(3)滤除活性炭的滤液,加入除钯硅胶搅拌吸附,滤除除钯硅胶;具体操作包括:(4) Take the filtrate from step (3) to filter out activated carbon, add palladium-removing silica gel to stir and absorb, and filter out palladium silica gel; specific operations include:
取有机相,加入伊万卡塞中间体V 0.1倍(m:m)量的除钯硅胶,40~60℃搅拌0.5~2小时,垫适量硅藻土过滤除钯硅胶,用适量二甲苯淋洗滤饼,得到滤除除钯硅胶的滤液。Take the organic phase, add 0.1 times (m:m) amount of palladium-removing silica gel of Ivankaser intermediate V, stir at 40-60°C for 0.5-2 hours, filter the palladium-removing silica gel with an appropriate amount of diatomaceous earth, and rinse with an appropriate amount of xylene The filter cake was washed to obtain a filtrate in which the palladium silica gel was removed by filtration.
(5)取步骤(4)滤除除钯硅胶的滤液,滴加盐酸/甲醇溶液,再加入甲基叔丁基醚并搅拌;滤出析出物,用甲醇/乙酸乙酯混合溶剂搅拌打浆;滤出固体,真空干燥至恒重,得除钯后的伊万卡塞中间体VI产品;具体操作包括:(5) Take step (4) to filter out the filtrate of palladium silica gel, add hydrochloric acid/methanol solution dropwise, then add methyl tert-butyl ether and stir; filter out the precipitate, stir and beat with methanol/ethyl acetate mixed solvent; Filter out solid, dry in vacuo to constant weight, obtain the Ivankasel intermediate VI product after removing palladium; Concrete operation comprises:
①向滤除除钯硅胶的滤液中滴加伊万卡塞中间体V 0.7倍(V:m)量的盐酸/甲醇溶液(盐酸:甲醇=1:2(m:m)),1小时内滴完;加入伊万卡塞中间体V 6倍(V:m)量的甲基叔丁基醚,搅拌1~2小时;① Add dropwise the hydrochloric acid/methanol solution (hydrochloric acid:methanol=1:2(m:m)) of Ivankasel intermediate V 0.7 times (V:m) to the filtrate from which the palladium silica gel was removed, within 1 hour After dripping; add 6 times (V:m) amount of methyl tert-butyl ether of Ivankaser intermediate V, and stir for 1-2 hours;
②过滤,滤饼用适量甲基叔丁基醚淋洗,抽至无明显液滴流出;湿品加入至伊万卡塞中间体V 5倍(V:m)量的甲醇/乙酸乙酯溶液(甲醇:乙酸乙酯=1:4(V:V))中打浆0.5~1小时,过滤;用适量乙酸乙酯淋洗并抽干;②Filter, rinse the filter cake with an appropriate amount of methyl tert-butyl ether, and pump until no obvious droplets flow out; add the wet product to a methanol/ethyl acetate solution that is 5 times (V:m) of Ivankaser intermediate V (methanol: ethyl acetate = 1:4 (V: V)) beating for 0.5~1 hour, filter; rinse with an appropriate amount of ethyl acetate and drain;
③滤饼在35~45℃下,真空干燥至恒重,得到类白色固体,即为伊万卡塞中间体VI。③ The filter cake was vacuum-dried at 35-45°C to constant weight to obtain an off-white solid, which was Ivankasel intermediate VI.
与现有技术相比,本发明的优点在于:通过综合使用L-半胱氨酸、活性炭和除钯硅胶,在多种吸附剂的共同作用下有效清除伊万卡塞中间体VI中残留的钯催化剂,保证伊万卡塞终产品的质量稳定,杜绝药品安全隐患。Compared with the prior art, the present invention has the advantages of: through the comprehensive use of L-cysteine, activated carbon and palladium-removing silica gel, under the joint action of various adsorbents, effectively remove the residual The palladium catalyst ensures the stable quality of Ivankaser's final product and eliminates potential drug safety hazards.
实施方式Implementation
下面根据实施例进一步说明本发明的技术方案。在本说明书的描述中,各实施例的内容意指结合其描述的具体技术特征包含于本发明的至少一个实施方式中。在本说明书中,对上述术语的示意性表述不一定指的是相同的实施方式或示例。而且,描述的具体技术特征可以在任何的一个或多个实施方式或示例中以合适的方式结合。The technical solution of the present invention will be further described below according to the embodiments. In the description of this specification, the content of each embodiment means that the specific technical features described in conjunction with it are included in at least one embodiment of the present invention. In this specification, schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the described specific technical features may be combined in any one or more implementations or examples in a proper manner.
(1)伊万卡塞中间体VI的合成(1) Synthesis of Ivankaser Intermediate VI
于1 L三颈瓶中加入10% 氢氧化钠 75 mL、二甲苯240 mL,升温至45~55℃;加入伊万卡塞中间体V 30 g,搅拌10min,分液,取上层有机相;有机相用纯化水75 mL洗涤一次;依次加入4-溴苯乙酸甲酯23 g、碳酸铯90 g、醋酸钯0.3 g和2-二环己基膦-2',4',6'-三异丙基联苯1.2 g,氮气保护;升温至100℃,反应4小时。Add 75 mL of 10% sodium hydroxide and 240 mL of xylene into a 1 L three-necked flask, heat up to 45~55 °C; add 30 g of Ivankaser intermediate V, stir for 10 min, separate the liquids, and take the upper organic phase; The organic phase was washed once with 75 mL of purified water; 23 g of methyl 4-bromophenylacetate, 90 g of cesium carbonate, 0.3 g of palladium acetate and 2-dicyclohexylphosphine-2',4',6'-triiso Propyl biphenyl 1.2 g, nitrogen protection; heat up to 100°C, react for 4 hours.
(2)L-半胱氨酸吸附除钯(2) L-cysteine adsorption to remove palladium
反应结束,加入纯化水300 mL,搅拌30min,静置分液;取有机相,加入2% L-半胱氨酸水溶液180 mL,搅拌0.5小时,分液;取有机相,加入2% L-半胱氨酸水溶液180 mL,搅拌0.5小时,分液; 取有机相加入25%氯化钠溶液180 mL,搅1小时,分液。After the reaction, add 300 mL of purified water, stir for 30 min, and let stand to separate the liquid; take the organic phase, add 180 mL of 2% L-cysteine aqueous solution, stir for 0.5 hours, and separate the liquid; take the organic phase, add 2% L-cysteine Take 180 mL of cysteine aqueous solution, stir for 0.5 hours, and separate the liquids; take the organic phase and add 180 mL of 25% sodium chloride solution, stir for 1 hour, and separate the liquids.
(3)活性炭吸附除钯(3) Palladium removal by activated carbon adsorption
有机相加入活性炭3 g,搅拌0.5小时,垫硅藻土15 g过滤,用二甲苯18 mL淋洗滤饼。Add 3 g of activated carbon to the organic phase, stir for 0.5 hours, filter with 15 g of diatomaceous earth, and rinse the filter cake with 18 mL of xylene.
(4)除钯硅胶吸附除钯(4) Palladium removal silica gel adsorption to remove palladium
取滤液加入除钯硅胶3 g,40℃搅拌0.5小时,垫硅藻土15 g过滤,用二甲苯18 mL淋洗滤饼。Add 3 g of palladium-free silica gel to the filtrate, stir at 40°C for 0.5 hour, filter with 15 g of diatomaceous earth, and rinse the filter cake with 18 mL of xylene.
(5)产品收集(5) Product collection
向滤液中滴加盐酸/甲醇溶液(盐酸6.6 mL、甲醇20 mL),加入甲基叔丁基醚180mL,搅拌1小时;Add hydrochloric acid/methanol solution (6.6 mL hydrochloric acid, 20 mL methanol) dropwise to the filtrate, add 180 mL methyl tert-butyl ether, and stir for 1 hour;
过滤,滤饼用甲基叔丁基醚30 mL淋洗,抽至无明显液滴流出;滤饼在35~40℃下,真空干燥10小时,恒重,得到类白色固体21.3 g。Filter, wash the filter cake with 30 mL of methyl tert-butyl ether, and pump until no obvious liquid drops flow out; the filter cake is vacuum-dried at 35-40 °C for 10 hours, and the weight is constant to obtain 21.3 g of off-white solid.
本实施例中生产的中间体VI,用于伊万卡塞的制备,最终所得伊万卡塞成品中,钯残留量小于2 ppm。The intermediate VI produced in this example is used for the preparation of Ivankaser, and the residual amount of palladium in the final Ivankaser finished product is less than 2 ppm.
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,根据本发明的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明的保护范围之内。The above is only a preferred embodiment of the present invention, but the scope of protection of the present invention is not limited thereto, any person familiar with the technical field within the technical scope disclosed in the present invention, according to the technical solution of the present invention Any equivalent replacement or change of the inventive concepts thereof shall fall within the protection scope of the present invention.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310563045.9A CN116693440A (en) | 2023-05-18 | 2023-05-18 | Method for removing palladium catalyst in Irelance intermediate VI synthesis process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310563045.9A CN116693440A (en) | 2023-05-18 | 2023-05-18 | Method for removing palladium catalyst in Irelance intermediate VI synthesis process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116693440A true CN116693440A (en) | 2023-09-05 |
Family
ID=87836536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310563045.9A Pending CN116693440A (en) | 2023-05-18 | 2023-05-18 | Method for removing palladium catalyst in Irelance intermediate VI synthesis process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116693440A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101560215A (en) * | 2009-05-27 | 2009-10-21 | 复旦大学 | Method for removing residual palladium of faropenem sodium |
| CN104230991A (en) * | 2014-08-25 | 2014-12-24 | 亿腾药业(泰州)有限公司 | Method for controlling palladium residue in fosaprepitant dimeglumine |
| CN105294547A (en) * | 2014-07-30 | 2016-02-03 | 连云港宏创药业有限公司 | Method for removing palladium from perampanel crude product |
| CN105517992A (en) * | 2013-09-05 | 2016-04-20 | 田边三菱制药株式会社 | Novel crystalline aralkylamine compound and its production method |
| CN110437076A (en) * | 2019-08-22 | 2019-11-12 | 江苏嘉逸医药有限公司 | A kind of synthetic method of high-purity hydrochloric acid cinacalcet |
-
2023
- 2023-05-18 CN CN202310563045.9A patent/CN116693440A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101560215A (en) * | 2009-05-27 | 2009-10-21 | 复旦大学 | Method for removing residual palladium of faropenem sodium |
| CN105517992A (en) * | 2013-09-05 | 2016-04-20 | 田边三菱制药株式会社 | Novel crystalline aralkylamine compound and its production method |
| CN105294547A (en) * | 2014-07-30 | 2016-02-03 | 连云港宏创药业有限公司 | Method for removing palladium from perampanel crude product |
| CN104230991A (en) * | 2014-08-25 | 2014-12-24 | 亿腾药业(泰州)有限公司 | Method for controlling palladium residue in fosaprepitant dimeglumine |
| CN110437076A (en) * | 2019-08-22 | 2019-11-12 | 江苏嘉逸医药有限公司 | A kind of synthetic method of high-purity hydrochloric acid cinacalcet |
Non-Patent Citations (3)
| Title |
|---|
| 徐松林等: "伊万卡塞合成研究", 《中国药物化学杂志》, vol. 32, no. 11, 30 November 2022 (2022-11-30), pages 839 - 842 * |
| 殷跃凡等: "清除偶联反应中钯残留方法的研究进展", 《中国医药工业杂志》, vol. 47, no. 6, 31 December 2016 (2016-12-31), pages 789 - 800 * |
| 郭志强等: "原子层沉积法制备巯丙基硅胶及其对 溶液中钯(Ⅱ)离子的吸附行为", 《高等学校化学学报》, vol. 30, no. 10, 31 October 2009 (2009-10-31), pages 2017 - 2023 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107501045B (en) | A kind of method that utilizes macroporous adsorption resin to separate and purify butanetriol from fermentation broth | |
| CN110117379B (en) | Adsorbing material for removing LDL (low density lipoprotein) in blood perfusion and preparation method thereof | |
| CN104557845B (en) | A kind of preparation method of lubiprostone compound | |
| CN103880945B (en) | The method of preparation high-purity thymalfasin | |
| CN102796262B (en) | Preparation method of sevelamer carbonate | |
| CN102010308B (en) | Preparation method of 8-hydroxyl caprylaldehyde of intermediate for synchronizing royaljelly acid | |
| CN116693440A (en) | Method for removing palladium catalyst in Irelance intermediate VI synthesis process | |
| CN103588750B (en) | Method for preparing ticagrelor intermediate | |
| CN103012382A (en) | Method for preparing olmesartan medoxomil | |
| CN102976948B (en) | Method for preparing nitisinone | |
| CN104774174B (en) | A kind of method of asymmetric syntheses S carbinoxamines | |
| CN116655507A (en) | A kind of idecalcitol dehydrated impurity and its preparation method and application | |
| CN103086845A (en) | Method for preparing L-menthol | |
| CN103119051A (en) | The preparation method of rocuronium bromide | |
| WO2015067689A1 (en) | Use of an organic-inorganic hybrid material for extracting uranium(vi) from a sulfuric acid aqueous solution, particularly from the sulfuric leaching of a uranium-bearing ore | |
| CN109928881A (en) | A kind of preparation method of cinacalcet hydrochloride | |
| CN111362974A (en) | Preparation method of fubitavir impurity | |
| CN110590675B (en) | Preparation of novel ionic liquid monomer and polymer thereof and application of novel ionic liquid monomer and polymer thereof in separation of tea polyphenol | |
| CN110256434A (en) | A method of preparing high-purity diprophylline | |
| CN115678026A (en) | A Chiral Functional Modified MOFs Adsorbent and Its Preparation and Application in Separation of Nicotine Enantiomers | |
| CN101980962B (en) | Method for removing halogen from liquid ammonia | |
| CN115007195B (en) | Preparation method and application of zeolite molecular sieve with low silicon-aluminum ratio | |
| CN1223588C (en) | Heterocyclic carboxylic ester reducing process | |
| JP2000351834A (en) | Calix [4] arene polymer, method for producing the same, and method for separating divalent lead ions using the same | |
| CN109651287A (en) | A kind of preparation method of 4- (4- aminophenyl) morpholone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |